Solid Tumor Clinical Trial
Official title:
A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies
Verified date | November 2023 |
Source | Processa Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced bladder cancer).
Status | Completed |
Enrollment | 127 |
Est. completion date | December 2019 |
Est. primary completion date | July 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Males or females who are 18 years or older - Able to swallow capsules - Histological or cytological evidence of confirmed metastatic pancreatic or advanced bladder cancer - Able to discontinue all anticancer therapies 2 weeks prior to study start - Measurable or evaluable disease using Response Evaluation Criteria in Solid Tumors - Life expectancy of at least 3 months - ECOG performance status of 0 or 1 - Provide written informed consent Exclusion Criteria: - Primary brain tumors or clinical evidence of active brain metastasis - Systemic corticosteroid use within 7 days before planned start of study therapy - Active infection requiring parenteral or oral antibiotics within 2 weeks before planned start of study therapy - Uncontrolled diabetes as assessed by the investigator - Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus - History of bone marrow of solid organ transplantation - History of congestive heart failure, arrhythmias, acute coronary syndrome or torsades de pointes - Any other medical, psychiatric, or social condition, which in the opinion of the investigator, would preclude participation in the study, pose an undue medical hazard, interfere with the conduct of the study, or interfere with interpretation of the study results - Known hypersensitivity to gemcitabine, azacytidine or cytosine arabinoside - Pregnant, planning a pregnancy or breast feeding during the study - Concurrent participation in another therapeutic clinical trial |
Country | Name | City | State |
---|---|---|---|
United States | Rexahn Site | Birmingham | Alabama |
United States | Rexahn Site | Duarte | California |
United States | Rexahn Site | Fairfax | Virginia |
United States | Rexahn Site | Las Vegas | Nevada |
United States | Rexahn Site | Miami | Florida |
United States | Rexahn Site | Miami Lakes | Florida |
United States | Rexahn Site | New York | New York |
United States | Rexahn Site | Saint Louis | Missouri |
United States | Rexahn Site | Salt Lake City | Utah |
United States | Rexahn Site | San Antonio | Texas |
United States | Rexahn Site | Skokie | Illinois |
United States | Rexahn Site | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
Processa Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Biomarker Concentrations in Blood (Phase 1 and Phase 2) | Analysis of biomarker data not conducted. Biomarker samples were not analyzed due to previous sponsor terminating clinical program. | Baseline and 4, 8, 12, 16 and 32 weeks | |
Primary | Overall Safety Profile Characterized by # of Subjects With Dose-limiting Toxicities (DLTs) in Phase 1 | Number of subjects participating in Phase 1 that experienced a DLT during the first cycle of treatment (28 days) | 28 days | |
Primary | Overall Safety Profile Characterized by Number of Subjects Experiencing Serious Adverse Events in Phase 1 | Number of subjects participating in Phase 1 that experience any SAEs | through study completion, up to 224 days (8 cycles of treatment) | |
Primary | Overall Safety Profile Characterized by the Number of Subjects That Discontinue Study Treatment - Phase 1 | Number of subjects participating in Phase 1 of study that discontinued study treatment due to a treatment emergent adverse event. | through study completion, up to 224 days (8 cycles of treatment) | |
Primary | Overall Safety Profile Characterized by Number of Subjects Experiencing a Treatment Emergent Adverse Event- Phase 1 | Number of subjects that experience any treatment-related adverse event. | through study completion, up to 224 days (8 cycles of treatment) | |
Primary | Progression Free Survival (Phase 2) | Progression Free Survival in Phase 2 of the study for pancreatic and bladder cancer subjects. | 4 months | |
Secondary | Area Under the Plasma Concentration Time Curve (AUC) (Phase 1) | Pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours after oral administration in Cycle 1 Days 1 and 15 | ||
Secondary | Best Overall Response Rate (Phase 2) | Best Overall Response Rate (includes Complete Response, Partial Response, and Stable Disease) | Baseline and at 4, 8, 12, 16 and 32 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |